The other side of immunoglobulin G: Suppressor of inflammation

Clinical and Experimental Immunology

Volumn 160, Issue 2, 2010, Pages 161-167

  Aschermann, S ^a   Lux, A ^a   Baerenwaldt, A ^a   Biburger, M ^a   Nimmerjahn, F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Fc receptors; Glycosylation; Immunoglobulin G; Inflammation; IVIG

Indexed keywords

COMPLEMENT COMPONENT C1Q; FC RECEPTOR; FC RECEPTOR IIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DRUG MECHANISM; GLYCOSYLATION; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, IGG;

EID: 77950651250     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04081.x     Document Type: Review

References (51)

1. Sylvestre D, Clynes R, Ma M, Warren H, Carroll MC, Ravetch JV. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J Exp Med 1996 184 : 2385 2392.
2. Nimmerjahn F, Ravetch JV. Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 2008 8 : 34 47.
3. Burton DR, Woof JM. Human antibody effector function. Adv Immunol 1992 51 : 1 84.
4. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002 2 : 580 592.
5. Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol 2002 14 : 798 802.
6. Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998 16 : 421 432.
7. Park SY, Ueda S, Ohno H et al. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J Clin Invest 1998 102 : 1229 1238.
8. Zhang M, Zhang Z, Garmestani K et al. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia. Cancer Res 2004 64 : 5825 5829.
9. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006 203 : 743 753.
10. Niwa R, Shoji-Hosaka E, Sakurada M et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004 64 : 2127 2133.
11. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005 310 : 1510 1512.
12. Kumar V, Ali SR, Konrad S et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 2006 116 : 512 520.
13. Shushakova N, Skokowa J, Schulman J et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest 2002 110 : 1823 1830.
14. Schmidt RE, Gessner JE. Fc receptors and their interaction with complement in autoimmunity. Immunol Lett 2005 100 : 56 67.
15. Daeron M, Lesourne R. Negative signaling in Fc receptor complexes. Adv Immunol 2006 89 : 39 86.
16. Bolland S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol 1999 72 : 149 177.
17. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Ann Rev Immunol 2008 26 : 513 533.
18. Crow AR, Lazarus AH. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev 2008 22 : 103 116.
19. Negi VS, Elluru S, Siberil S et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007 27 : 233 245.
20. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981 1 : 1228 1231.
21. Debre M, Bonnet MC, Fridman WH et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993 342 : 945 949.
22. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003 18 : 573 581.
23. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 2006 203 : 789 797.
24. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001 291 : 484 486.
25. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol 2000 18 : 739 766.
26. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007 7 : 715 725.
27. Li N, Zhao M, Hilario-Vargas J et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005 115 : 3440 3450.
28. Clarkson SB, Kimberly RP, Valinsky JE et al. Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med 1986 164 : 474 489.
29. Soubrane C, Tourani JM, Andrieu JM et al. Biologic response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient. Blood 1993 81 : 15 19.
30. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009 113 : 3154 3160.
31. Teeling JL, Jansen-Hendriks T, Kuijpers TW et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001 98 : 1095 1099.
32. Song S, Crow AR, Freedman J, Lazarus AH. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 2003 101 : 3708 3713.
33. Song S, Crow AR, Siragam V, Freedman J, Lazarus AH. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 2005 105 : 1546 1548.
34. Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006 12 : 688 692.
35. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002 100 : 2087 2093.
36. Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 2004 113 : 1328 1333.
37. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 313 : 670 673.
38. Shields RL, Namenuk AK, Hong K et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001 276 : 6591 6604.
39. Tackenberg B, Jelcic I, Baerenwaldt A et al. Impaired inhibitory Fc gamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci USA 2009 106 : 4788 4792.
40. Fukuyama H, Nimmerjahn F, Ravetch JV. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol 2005 6 : 99 106.
41. Ono M, Okada H, Bolland S et al. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Cell 1997 90 : 293 301.
42. Xiang Z, Cutler AJ, Brownlie RJ et al. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 2007 8 : 419 429.
43. Baerenwaldt A, Nimmerjahn F. Immune regulation - Fc gamma RIIB - regulating the balance between protective and autoreactive immune responses. Immunol Cell Biol 2008 86 : 482 484.
44. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007 25 : 21 50.
45. Mizuochi T, Hamako J, Nose M, Titani K. Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice. J Immunol 1990 145 : 1794 1798.
46. Parekh RB, Dwek RA, Sutton BJ et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985 316 : 452 457.
47. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995 1 : 237 243.
48. Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci USA 2007 104 : 8433 8437.
49. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007 44 : 1524 1534.
50. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008 320 : 373 376.
51. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008 105 : 19571 19578.